Compare POWWP & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWWP | GRMLW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 63 | 5 |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
| Metric | POWWP | GRMLW |
|---|---|---|
| Price | $24.35 | $0.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5K | ★ 15.7K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.90 | $0.08 |
| 52 Week High | $25.50 | $0.38 |
| Indicator | POWWP | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 52.50 | 29.55 |
| Support Level | $23.58 | N/A |
| Resistance Level | $24.57 | $0.17 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 76.15 | 4.55 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.